Jacques Tebib

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. ncbi Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
    Jacques Tebib
    Service de Rhumatologie, Centre Hospitalier Lyon Sud, 765 chemin du Grand Revoyet, 69495 Pierre Benite, France
    Arthritis Res Ther 11:R95. 2009
  2. ncbi Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Frédéric Lavie
    Service de Rhumatologie, Hopital de Bicetre, Le Kremlin Bicetre, France
    Joint Bone Spine 74:346-52. 2007
  3. ncbi Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion
    Emmanuelle Dernis
    Service de Rhumatologie, Centre Hospitalier, Le Mans, France
    Joint Bone Spine 76:524-31. 2009
  4. ncbi Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion
    Emmanuelle Dernis
    Service de Rhumatologie, Centre Hospitalier Le Mans, 72037 Le Mans, France
    Joint Bone Spine 77:451-7. 2010
  5. ncbi Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials
    Anne Fouque-Aubert
    Service de Rhumatologie, Universite Lyon 1, Hôpital Lyon Sud, Pierre Benite, France
    Ann Rheum Dis 69:1756-61. 2010
  6. ncbi Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Emmanuelle Dernis
    Service de Rhumatologie, CH Le Mans, Le Mans, France
    Joint Bone Spine 74:330-7. 2007
  7. ncbi Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, Marseille, France
    Joint Bone Spine 73:379-87. 2006
  8. ncbi A new target for autoantibodies in patients with rheumatoid arthritis
    Magali Robert Pachot
    Hospices Civils de Lyon, INSERM U851, Lyon Sud Hospital, Department of Immunology, 69495 Pierre Benite, France
    Ann N Y Acad Sci 1108:382-91. 2007

Collaborators

Detail Information

Publications8

  1. ncbi Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
    Jacques Tebib
    Service de Rhumatologie, Centre Hospitalier Lyon Sud, 765 chemin du Grand Revoyet, 69495 Pierre Benite, France
    Arthritis Res Ther 11:R95. 2009
    ..This study evaluates the safety and efficacy of masitinib (AB1010), a potent and selective protein tyrosine kinase inhibitor of c-KIT, in the monotherapy treatment of DMARD-refractory RA...
  2. ncbi Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Frédéric Lavie
    Service de Rhumatologie, Hopital de Bicetre, Le Kremlin Bicetre, France
    Joint Bone Spine 74:346-52. 2007
    ..To develop recommendations about pharmacotherapy (excluding biotherapeutic agents) in patients with axial forms of ankylosing spondylitis (AS) seen in everyday clinical practice...
  3. ncbi Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: development of recommendations for clinical practice based on data from the literature and experts opinion
    Emmanuelle Dernis
    Service de Rhumatologie, Centre Hospitalier, Le Mans, France
    Joint Bone Spine 76:524-31. 2009
    ..To develop recommendations about treatment (except anti-TNF agents) of psoriatic arthritis with peripheral joint involvement (PsA) seen in everyday practice, using evidence from the literature, supplemented with expert opinion when needed...
  4. ncbi Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion
    Emmanuelle Dernis
    Service de Rhumatologie, Centre Hospitalier Le Mans, 72037 Le Mans, France
    Joint Bone Spine 77:451-7. 2010
    ..To develop recommendations about the use of glucocorticoids in patients with established rheumatoid arthritis (RA) managed in everyday practice, using the evidence-based approach and expert opinion...
  5. ncbi Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials
    Anne Fouque-Aubert
    Service de Rhumatologie, Universite Lyon 1, Hôpital Lyon Sud, Pierre Benite, France
    Ann Rheum Dis 69:1756-61. 2010
    ..Despite wide use of TNF blockers in ankylosing spondylitis (AS), the infection risk has never been evaluated in this disease...
  6. ncbi Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Emmanuelle Dernis
    Service de Rhumatologie, CH Le Mans, Le Mans, France
    Joint Bone Spine 74:330-7. 2007
    ..To develop French recommendations about the clinical and laboratory follow-up of patients with axial ankylosing spondylitis (AS) seen in everyday practice...
  7. ncbi Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, Marseille, France
    Joint Bone Spine 73:379-87. 2006
    ....
  8. ncbi A new target for autoantibodies in patients with rheumatoid arthritis
    Magali Robert Pachot
    Hospices Civils de Lyon, INSERM U851, Lyon Sud Hospital, Department of Immunology, 69495 Pierre Benite, France
    Ann N Y Acad Sci 1108:382-91. 2007
    ..In conclusion, this study demonstrates new autoantibodies in RA patients that are directed against carbonic anhydrase III. The sensitivity and specificity of these new autoantibodies for RA have to be further evaluated...